Participant experiences in a kidney failure care intervention in the navigate-kidney study
Peer-Reviewed Publication
Peer-Reviewed Publication
Medicine & Health
Updates every hour. Last Updated: 7-Nov-2025 21:11 ET (8-Nov-2025 02:11 GMT/UTC)
Peer-Reviewed Publication
7-Nov-2025
Community health worker support for Hispanic and Latino individuals receiving hemodialysis
JAMA NetworkPeer-Reviewed Publication
About The Study: In this randomized clinical trial, a culturally tailored community health worker intervention modestly lowered interdialytic weight gain and improved dialysis adherence and patient activation among Hispanic and Latino patients with hemodialysis-dependent kidney failure.
- Journal
- JAMA Internal Medicine
7-Nov-2025
Chronic kidney disease has more than doubled since 1990, now affecting nearly 800 million people worldwide
Institute for Health Metrics and EvaluationPeer-Reviewed Publication
SEATTLE, Wash. – Nov. 7, 2025 – The number of adults living with chronic kidney disease (CKD) has more than doubled since 1990, reaching nearly 800 million worldwide, according to new research published in The Lancet. The findings come from the Global Burden of Disease (GBD) 2023 study, which tracked CKD trends among adults age 20 years and older across 204 countries and territories from 1990 through 2023.
- Journal
- The Lancet
- Meeting
- ASN Kidney Week
7-Nov-2025
Chronic kidney disease is now the ninth leading cause of death
NYU Langone Health / NYU Grossman School of MedicinePeer-Reviewed Publication
Record numbers of men and women globally are now estimated to have reduced kidney function, a new study shows. Figures rose from 378 million people with the disease in 1990 to 788 million in 2023 as the world population grew and aged, making it for the first time a top 10 cause of death worldwide.
- Journal
- The Lancet
- Funder
- NIH/National Institutes of Health, Bill and Melinda Gates Foundation, National Kidney Foundation
- Meeting
- ASN Kidney Week
7-Nov-2025
SGLT2 inhibitors and kidney outcomes by glomerular filtration rate and albuminuria
JAMA NetworkPeer-Reviewed Publication
About The Study: The findings of this study support the routine use of sodium-glucose cotransporter 2 (SGLT2) inhibitors to improve kidney outcomes across the full spectrum of kidney function and albuminuria among patients with type 2 diabetes, chronic kidney disease, or heart failure.
- Journal
- JAMA
7-Nov-2025
Sotagliflozin outperforms dapagliflozin for reducing salt- sensitive hypertension and kidney injury in rats
American Society of NephrologyReports and Proceedings
Dual inhibition of sodium-glucose co-transporters 1 and 2 with the recently approved drug sotagliflozin may be an especially effectivetreatment for salt- sensitive hypertension.
The findings will be presented at American Society of Nephrology (ASN)Kidney Week 2025 November 5–9.
- Meeting
- ASN Kidney Week
7-Nov-2025
Trial analysis reveals almost all adults with hypertensive chronic kidney disease would benefit from intensive blood pressure lowering
American Society of NephrologyReports and Proceedings
Nearly all SPRINT participants with hypertension and nondiabetic chronickidney disease stages 3–4 had a net benefit (the predicted difference between benefits and harms) that favored a systolic blood pressure target of <120 mm Hg compared with <140 mm Hg.
The findings will be presented at American Society of Nephrology (ASNKidney Week 2025 November 5–9.
- Meeting
- ASN Kidney Week